AUTHORS
Yongxian HU, MD, Mingming Zhang, PhD2, Shan Fu3, Jingchao Liu4, Jingjing Feng, MD5, Xin Guo6, Pingnan Xiao7, Shiping Jiao, MD, PhD8, He Huang, MD, PhD9
AFFILIATIONS
1 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
2 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
3 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
4 TCRx Therapeutics Co. Ltd., Nanjing, Jiangsu, China
5 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
6 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
7 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
8 TCRx Therapeutics Co. Ltd., Nanjing, Jiangsu, China
9 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
ABSTRACT
Background:
The off-the-shelf nature of in vivo CAR-T products eliminates the need for apheresis, lymphodepleting and bridging therapy. Clinical lab assessments on systemic inflammatory biomarkers and hepatic transaminases of lentiviral vector (LVV) based in vivo CAR-T have shown a biphasic pattern: an early inflammatory storm within 24 hours post-infusion characterized by spikes of hepatic transaminases and cytokines and a second “wave” alongside CAR-T expansion. Infusion-related reactions (IRRs) arising from the early inflammatory storm mandated the prophylactic corticosteroids to minimize adverse events. Here, we report the preliminary phase 1 study results in r/r B-ALL patients (pts) of KSV01—an immunoquiescent-designed, third-generation LVV based in vivo CAR-T selectively transducing circulating T cells to generate anti-CD19 CAR-T cells aiming to attenuate the early-phase inflammatory storm characteristic of this therapeutic class.
Methods:
We conducted a single-arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 in r/r B-ALL (NCT07246707). Primary endpoint was safety and tolerability within 28 days post-infusion and adverse events were graded according to the Common Terminology Criteria for Adverse Events (v6.0). Pts aged 18–80 years with r/r B-ALL diagnosed per 2016 WHO classification, ECOG score 0–1, adequate end-organ function, and ≥ 5% of blast cells in bone marrow (BM) with CD19 positive leukemic cells were recruited. Four dose levels (DLs) were predefined—0.2E8, 0.6E8, 2E8, and 4E8 transduction units (TU)—with accelerated titration for the first 2 dose cohorts. KSV01 was administered intravenously without prior apheresis, lymphodepleting conditioning or prophylactic corticosteroids.
Results:
Eight eligible patients (aged 19-72) with 2-4 prior therapies were enrolled. Among them, 2 pts had Philadelphia chromosome-positive (Ph+) leukemia. In the accelerated titration phase, 1 pt was enrolled in each of DL1 and DL2, and 3 pts in each of DL3 and DL4. The median baseline BM blast cells was 16% (range, 5%–67%). One pt had extramedullary disease; 2 pts had prior allogenic hematopoietic stem cell transplantation; 1 pt had prior anti-CD19 CAR-T cell therapy.
All pts experienced treatment-emergent adverse events. IRRs were transient and manageable (all at Gr 1) and occurred in 6 pts (3 at DL3, 3 at DL4). No AEs of transaminase increase were observed through 24 hours post-infusion except 1 pt (DL3) with baseline aspartate aminotransferase (AST) and γ-glutamyl transferase (GGT) exceeding the upper limit of normal at 118 and 413 U/L, respectively, which increased to 281 and 489 U/L at 24 hours post-infusion and returned to baseline at Day 3. CRS was observed in 7 pts concurrently with CAR-T expansion; 5 events were Gr 1 (3 at DL3, 2 at DL4); 2 Ph+ ALL pts experienced Gr 2 (DL1) and Gr 3 (DL4) CRS, respectively. No ICANS or delayed neurotoxicity were observed. AEs greater than Gr 3 were leukopenia (8/8), neutropenia (4/8), anemia (4/8), thrombocytopenia (4/8), ALT increase (1/8), AST increase (1/8), total bilirubin increase (1/8), GGT increase (2/8), hypertriglyceridemia (2/8), fibrinogen decrease (1/8), hypocalcemia (1/8), hyperkalemia (1/8), hypokalemia (1/8), hyponatremia (1/8) and hypermagnesemia (1/8); all AEs had resolved and no dose limiting toxicity occurred.
Three pts reached best response of CR/CRi (1 at DL3, 2 at DL4), and 2 of these had BM minimal residual disease negativity (MRD-) at first disease evaluation. One pt (DL3) had CD19 negativity through D50 but CD22 positive relapse occurred. In 5 pts with peripheral CAR-T expansion, the median peripheral peak percentage of CD3+CAR+/CD3+ T cells was 51.4% (range, 9.13%–94.2%) corresponding to the median peak CAR+ T cell count of 502.04 cells/μL (range, 8.77–29580.72 CAR+ T cells); median time to peak expansion (Tmax) was 13 days post-infusion (range, 11–18 days).
Conclusions:
Preliminary phase 1 results showed that KSV01, an off-the-shelf, immunoquiescent-designed in vivo CAR-T therapy, was well tolerated, with a manageable post-infusion cytokine release profile following LVV administration without prophylactic corticosteroids. This vector also showed preliminary activity, manageable toxicities, and CAR-T cell expansions in r/r B-ALL pts. Clinical study at higher dose levels is needed to further explore its efficacy, safety and in vivo CAR-T generation and expansion profile in r/r B-ALL pts.
DISCLOSURES
Yongxian HU, MD: No relevant conflicts of interest to declare.